---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-26-007845"
form_type: "8-K"
ticker: "SBFM"
cik: "0001402328"
company_name: "Sunshine Biopharma Inc."
filed_at: "2026-10-14T20:05:13+00:00"
generated_at: "2026-10-14T20:06:07.347325+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.55
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Sunshine Biopharma CEO's 90% consent approves discounted share issuance and Series D warrant repricing

## Summary
- Dr. Steve N. Slilaty, CEO and holder of ~90% of voting power, approved the matters by written consent on October 13, 2026.
- Consent covers issuing more than 20% of outstanding common stock at a deemed discount to the Nasdaq Minimum Price, tied to the public offering that closed October 9, 2026.
- Also approves exercise-price/share-count adjustments to Series D Warrants in a Share Combination Event (Section 3.7) and voluntary repricing of all outstanding Series D Warrants (Section 3.8).
- Consent becomes effective 20 days after the definitive information statement is mailed to stockholders.
- Common stock trades as SBFM and the purchase warrants as SBFMW on Nasdaq.

## SEC filing metadata
- accession: 0001683168-26-007845
- form_type: 8-K
- ticker: SBFM
- cik: 0001402328
- company_name: Sunshine Biopharma Inc.
- filed_at: 2026-10-14T20:05:13+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.55
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1402328/000168316826007845/0001683168-26-007845-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1402328/000168316826007845/sunshine_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-26-007845
- JSON: https://secwatch.observer/filing/0001683168-26-007845.json
- Plain text: https://secwatch.observer/filing/0001683168-26-007845.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.